Navigation Links
Study offers evidence that sunscreen use in childhood prevents melanoma in adults
Date:6/19/2014

SAN ANTONIO, June 19, 2014 Research conducted at the Texas Biomedical Research Institute, published in the latest issue of the scientific journal Pigment Cell and Melanoma, has established unequivocally in a natural animal model that the incidence of malignant melanoma in adulthood can be dramatically reduced by the consistent use of sunscreen in infancy and childhood.

According to senior author John L. VandeBerg, Ph.D., the research was driven by the fact that, despite the increasing use of sunscreen in recent decades, the incidence of malignant melanoma, the most aggressive form of skin cancer, continues to increase dramatically. The American Cancer Society estimates that more than 75,000 new cases of melanoma will be diagnosed in the U.S. this year.

"While sunscreen is highly effective in preventing sunburn, this paradox has led some to question whether sunscreen is effective in preventing melanoma caused by ultraviolet (UV) light," VandeBerg said. "It has been suggested that sunscreen enables people to receive more UV exposure without becoming sunburned, and that increased exposure to UV light has led to an increasing incidence of melanoma."

Questions regarding the effectiveness of sunscreen have remained unanswered in part because, until recently, no natural mammalian model of UV-induced melanoma has existed, noted VandeBerg. Scientists at Texas Biomedical Research Institute have established the gray short-tailed opossum, a small marsupial from South America, as such a model, and tested an over-the-counter facial lotion containing SPF15 sunscreen for its ability to prevent UV-induced melanoma.

The Texas Biomed researchers found that the application of lotion containing sunscreen to infant opossums led to a 10-fold reduction in pre-melanotic lesions (known to progress to melanoma), in comparison to infant opossums receiving lotion that did not contain sunscreen. This difference in the development of lesions occurred even when low doses of UV light were applied so low that they caused no sunburn or even reddening of the skin in the opossums that did not receive sunscreen.

The pre-melanotic lesions did not appear until the infants had become adolescents (equivalent to early teenagers in humans), and prior experiments established that the pre-melanocytic lesions in opossums do not progress to melanomas until the animals are well into adulthood, as typically occurs in humans.

"Based on these results, we speculate that the reason it is particularly important that sunscreens be used consistently in childhood, and especially in infancy, is because skin cells during growth are dividing much more rapidly than in adulthood, and it is during cell division that the cells are most susceptible to UV-induced damage," said VandeBerg. "Evidence that supports this hypothesis is that melanoma is not induced in adult opossums when their shaved skin is irradiated by UV light in the absence of sunscreen."


'/>"/>

Contact: Mary Uhlig
muhlig@dublinandassociates.com
210-227-0221 x223
Texas Biomedical Research Institute
Source:Eurekalert

Related medicine news :

1. Penn study reveals a common genetic link in fatal autoimmune skin disease
2. Pharmacy study expects to lower hospital readmissions
3. Study finds difference in way bipolar disorder affects brains of children versus adults
4. Proposed childrens study needs refinement, report finds
5. Study examines how brain reboots itself to consciousness after anesthesia
6. U of MD researchers receive NIH grant to study personalized medicine for genetic diabetes
7. New study is first to identify, clarify MERS-related abnormality distribution on CT
8. Study shows cost-effectiveness of smoking cessation counseling during hospitalization
9. TGen and Scottsdale Healthcare begin study of new drug for patients with solid tumors
10. Gut bacteria predict survival after stem cell transplant, study shows
11. E-cigs heavily marketed on Twitter, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Raton (PRWEB) , ... September 19, 2017 , ... ... the El Naturalista brand, developed by ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. ... in Spain, and El Naturalista is a trusted, well-respected brand reliant on the ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to ... calculating their cardiovascular disease (CVD) risk in the next 10 years. , Imagine ... an estimated 10-year risk prediction! , Imagine if the weatherman says there is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... with the Davidson Fellows Scholarship on September 27 at a reception in Washington ... Technology, Engineering, Mathematics, Literature and Music. , “I am honored to be a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency nursing expertise, skill ... Emergency Nurse (CEN®) certification according to a large-scale study announced today by ... conducted by the Human Resources Research Organization (HumRRO) in late 2016 and early ...
(Date:9/18/2017)... Bangkok, Thailand (PRWEB) , ... September 19, 2017 ... ... in Asia Pacific’s protein ingredient market , expected to grow at the ... Frost & Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
Breaking Medicine Technology: